Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gustin Gene Polymorphism and 6-n-propylthiouracil (PROP) Taste (gustinprop)

This study has been completed.
Sponsor:
Information provided by:
University of Cagliari
ClinicalTrials.gov Identifier:
NCT01097915
First received: April 1, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted
  Purpose

The investigators investigate the possible association of PROP taste with gustin gene polymorphism rs2274333 (A/G), salivary zinc ion concentration and BMI.


Condition
PROP Taste Sensitivity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Sensitivity to 6-n-propylthiouracil (PROP) Association With Gustin (CA6) Gene Polymorphism, Salivary Zinc and BMI in Humans

Resource links provided by NLM:


Further study details as provided by University of Cagliari:

Primary Outcome Measures:
  • association between gustin gene polymorphism and PROP sensitivity [ Time Frame: 7 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • association between PROP sensitivity, Saliva zinc ion concentration and BMI [ Time Frame: 7 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

DNA and zinc analyses in saliva


Enrollment: 75
Study Start Date: October 2009
Study Completion Date: April 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
PROP taste sensitivity

  Eligibility

Ages Eligible for Study:   20 Years to 30 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Seventy-five non-smoking volunteers (28 men and 47 women) were recruited for the study. Mean age was 25 y, ranging from 20 to 29 y. Thresholds for the 4 basic tastes were evaluated in all subjects in order to rule out any gustatory impairment. The volunteers showed no variation of body weight > 5 kg over the last 3 mo. They were not following a prescribed diet or using medications that might interfere with taste perception; none had food allergies. They were assessed for cognitive eating behaviours using the Three-Factor Eating Questionnaire

Criteria

Inclusion Criteria:

  • no variation of body weight > 5 kg over the last 3 mo BMI within 20-25 Age between 20-30

Exclusion Criteria:

  • gustatory impairment following a prescribed diet or using medications that might interfere with taste perception food allergies smokers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01097915

Locations
Italy
Sezione di Farmacologia Clinica del Dipartimento di Neuroscienze, San Giovanni di Dio Azienda Ospedaliero Universitaria di Cagliari
Cagliari, Ca, Italy, 09124
Sponsors and Collaborators
University of Cagliari
Investigators
Principal Investigator: Iole Tomassini Barbarossa, PhD Dipartimento di Biologia Sperimentale Sezione di Fisiologia Generale Università di Cagliari
  More Information

No publications provided

Responsible Party: Iole Tomassini Barbarossa, Università di Cagliari
ClinicalTrials.gov Identifier: NCT01097915     History of Changes
Other Study ID Numbers: UNICADBSITB-1
Study First Received: April 1, 2010
Last Updated: April 1, 2010
Health Authority: Italy: National Bioethics Committee

Keywords provided by University of Cagliari:
PROP taste sensitivity
Gustin (CAVI) polymorphism
Salivary zinc
BMI

Additional relevant MeSH terms:
Propylthiouracil
Antimetabolites
Antithyroid Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 20, 2014